Trial Profile
Phase 2 Trial of Dose Dense (Weekly) Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 30 Sep 2022 Status changed from active, no longer recruiting to completed.
- 03 Jun 2020 Planned End Date changed from 1 Sep 2021 to 1 Sep 2023.
- 03 Jun 2020 Planned primary completion date changed from 1 Sep 2020 to 1 Sep 2021.